Navigation Links
Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments
Date:7/9/2008

e the non invasive therapy available. USHIFU is also funding FDA-approved clinical trials in the United States to gather data important for analysis of the technology by the FDA. The first is a pivotal trial for the treatment of primary organ confined prostate cancer that will enroll 466 participants at 24 different centers. A second pivotal trial will begin for the treatment of recurrent prostate cancer in men who have failed external beam radiation therapy. This single arm study will enroll 202 participants at 10 different sites.

About the Sonablate(R) 500

The Sonablate(R) 500 is a non invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by FSI and is manufactured by Misonix, Inc. (Nasdaq: MSON) who also holds distribution rights in Europe. Takai Hospital Supply Ltd. and THS International distribute the Sonablate(R) 500 in Southeast Asia and the Middle East.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate cancer.


'/>"/>
SOURCE USHIFU
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
4. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
7. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
8. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Al Novak Elected Chairman of the Board of OrbusNeich Medical 2Star Scientific Breaks New Ground Plans FDA Filing for Approval of First Modified Risk Tobacco Product 3B Nominates Curtis Wright MD MPH for FDA Ad 57981 1Star Scientific Breaks New Ground Plans FDA Filing for Approval of First Modified Risk Tobacco Product 3B Nominates Curtis Wright MD MPH for FDA Ad 57981 2Star Scientific Breaks New Ground Plans FDA Filing for Approval of First Modified Risk Tobacco Product 3B Nominates Curtis Wright MD MPH for FDA Ad 57981 3Star Scientific Breaks New Ground Plans FDA Filing for Approval of First Modified Risk Tobacco Product 3B Nominates Curtis Wright MD MPH for FDA Ad 57981 4Star Scientific Breaks New Ground Plans FDA Filing for Approval of First Modified Risk Tobacco Product 3B Nominates Curtis Wright MD MPH for FDA Ad 57981 5New Reagents from New England Biolabs Bring Purity and Increased Value to Sample Prep for Next Generation Sequencing 57976 1Advantage Business Media Launches Enhanced Websites 57972 1Advantage Business Media Launches Enhanced Websites 57972 2Advantage Business Media Launches Enhanced Websites 57972 3